News >

Celgene Acquiring Juno Therapeutics for $9 Billion

Silas Inman @silasinman
Published: Monday, Jan 22, 2018

Mark J. Alles

Mark J. Alles
Celgene has announced plans to acquire Juno Therapeutics, which is the developer of the chimeric antigen receptor (CAR) T-cell therapy liso-cel (lisocabtagene maraleucel; JCAR017), for per share, totaling approximately billion. The decision was approved by both companies and is expected to complete within the first quarter of 2018.

Initially following the transaction, the Celgene noted there would be a {{text}}.50 dilution in earnings per share. In the long-term, however, Celgene anticipates earnings per share of .50 in 2020.
References:
  1. Abramson JS, Palomba ML, Gordon LI, et al. High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2017; Atlanta, Georgia. Abstract 581.
  2. Gilbert MJ. Severe neurotoxicity in the phase 2 trial of JCAR015 in adult B-ALL (ROCKET Study): analysis of patient, protocol and product attributes. Presented at: 32nd Annual SITC Meeting, National Harbor, MD, November 8-12.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x